Home » Stocks » Anchiano Therapeutics

Anchiano Therapeutics Ltd. (ANCN)

Stock Price: $1.31 USD -0.19 (-12.67%)
Updated Jul 10, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 9.72M
Revenue (ttm) n/a
Net Income (ttm) -12.21M
Shares Out 7.42M
EPS (ttm) -2.79
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 10, 2020
Last Price $1.31
Previous Close $1.50
Change ($) -0.19
Change (%) -12.67%
Day's Open 1.44
Day's Range 1.31 - 1.45
Day's Volume 82,527
52-Week Range 0.51 - 4.65

More Stats

Market Cap 9.72M
Enterprise Value n/a
Earnings Date (est) Aug 10, 2020
Ex-Dividend Date n/a
Shares Outstanding 7.42M
Float 3.08M
EPS (basic) -1.45
EPS (diluted) -2.79
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 14,275
Short Ratio 0.13
Short % of Float n/a
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 1.00
Revenue n/a
Operating Income -21.01M
Net Income -12.21M
Free Cash Flow n/a
Net Cash 13.80M
Net Cash / Share 1.86
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -40.89%
ROE -109.45%
ROIC 790.50%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (1)

Buy 0
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Hold

Price Target

Current: 1.31
Target: 1.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-22.90-13.04-9.39-4.64
Net Income-27.12-13.80-9.81-4.74
Shares Outstanding34.4512.6332.86-
Earnings Per Share-3.95-5.45-5.45-4.35
Operating Cash Flow-16.46-14.22-8.52-3.73
Capital Expenditures-0.10-0.21-0.03-0.08
Free Cash Flow-16.55-14.44-8.55-3.81
Cash & Equivalents17.587.521.454.56
Total Debt1.12---
Net Cash / Debt16.467.521.454.56
Book Value14.919.81-0.613.30
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Anchiano Therapeutics Ltd.
Country Israel
Employees 16
CEO Frank G. Haluska

Stock Information

Ticker Symbol ANCN
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ANCN


Anchiano Therapeutics Ltd, a clinical-stage biotechnology company, develops gene therapies to treat early-stage bladder cancer. It is primarily developing Inodiftagene that is in various clinical trials for the treatment of non-muscle-invasive bladder cancer. The company was formerly known as BioCancell Ltd. and changed its name Anchiano Therapeutics Ltd in July 2018. The company was founded in 2004 and is headquartered in Cambridge, Massachusetts.